

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

The therapy of chronic pouchitis

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1706994> since 2019-07-19T16:09:23Z

Published version:

DOI:10.23736/S1121-421X.18.02551-5

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

The therapy of chronic pouchitis

Journal: Minerva Gastroenterologica e Dietologica

Paper code: Minerva Gastroenterol Dietol-2551

Submission date: December 8, 2018

Article type: Editorial

Files:

1. Manuscript

Version: 1

Description: manoscritto

File format: application/octet-stream

The therapy of chronic pouchitis

1
2
3
4
5
6 Davide Giuseppe Ribaldone¹ *, Andrea Resegotti², Marco Astegiano³
7
8
9

10
11 ¹Department of Surgical Sciences, University of Turin, Turin, Italy;
12

13 ²CHIRURGIA GENERALE 1 U, Città della Salute e della Scienza, Turin, Italy;
14

15 ³Gastroenterology-U, Department of General and Specialist Medicine, Città della Salute e della
16 Scienza, Turin, Italy
17
18

19
20
21
22 Conflicts of interest: none to declare.
23
24
25
26
27

28 *Corresponding author: Davide Giuseppe Ribaldone - Department of Surgical Sciences, University of
29 Turin, Turin, Italy, C.so Bramante 88 - 10126 Torino - Italy. E-mail: davrib_1998@yahoo.com Tel:
30 +390116333918, Fax: +390116333623.
31
32
33
34
35
36
37

38 **Key words:** Biologics – Pouchitis – Predictors - Treatment - Ulcerative colitis
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1 Ulcerative colitis (UC) is an inflammatory bowel disease characterized by inflammation restricted to
2
3 the large bowel mucosa. Up to one-quarter of patients with UC will eventually undergo total
4
5 proctocolectomy.¹
6
7

8 Since the first description by Parks in 1978, ileal pouch-anal anastomosis (IPAA) has become the
9
10 surgical procedure of choice for both UC refractory to medical therapy and in those who develop
11
12 colonic dysplasia or cancer and familial adenomatous polyposis (FAP).²
13
14

15 Since UC is primarily restricted to the large bowel, it was expected that IPAA will enable eradication of
16
17 diseased and cure the UC. However, following the surgery up to 30% may develop chronic pouchitis.³
18
19

20 Pouchitis is clinically characterised by symptoms that include increased stool frequency,
21
22 haematochezia, abdominal cramping, urgency, tenesmus, incontinence, fever and extraintestinal
23
24 manifestations.
25
26

27 Pouchitis is a nonspecific inflammatory condition in the ileal pouch reservoir.⁴ The fact that pouchitis
28
29 occurs more commonly in those who have a pouch for UC than for FAP suggests that both the immune
30
31 system and its regulation have a role in the aetiology. Some evidence suggests that an abnormal
32
33 mucosal immune response to altered microflora in the ileal pouch leads to inflammation.
34
35
36

37 The diagnosis of pouchitis has no standard definition. The most commonly used criterion is the pouch
38
39 disease activity index (PDAI). The PDAI is a composite score including clinical symptoms, endoscopic
40
41 findings and histological findings. A score greater than 7 is required for a diagnosis of pouchitis.
42
43
44

45 Differential diagnosis of pouchitis include pouch ischemia, pouch stenosis, impaired pouch emptying,
46
47 infectious diarrhea such as cytomegalovirus or clostridium difficile, Crohn's disease (CD) of the pouch,
48
49 adhesions.
50
51

52 Controversy remains about anal and vaginal fistulas in patients with a pouch and what they represent. It
53
54
55

1 is possible that some of these are due to CD, whereas others are caused by underlying pelvic sepsis,
2
3
4 surgical complication or cryptoglandular sepsis distinct from CD.⁵

5
6 Although the majority of patients with pouchitis respond favourably to antibiotic therapy, particularly
7
8 in the initial stage of the disease, in the longer term, in many patients pouchitis becomes refractory to
9
10 conventional antibiotic therapy. In practice, antibiotics are often needed to maintain symptomatic
11
12 response and symptoms return on withdrawal.
13
14

15
16 Chronic pouchitis has no standard definition, but is often defined as the need for antibiotics for greater
17
18 than 4 weeks with evidence of pouchitis.⁶ Chronic pouchitis develops in approximately 5%-19% of
19
20 patients who either become dependent on antibiotics for symptom relief or have symptoms refractory to
21
22 conventional therapies.⁷

23
24
25 Regarding primary prophylaxis of pouchitis, a low-carbohydrate, low-fibre, and high-protein diet is
26
27 recommended at baseline. In a randomized trial of 40 consecutive patients who underwent IPAA were
28
29 given either probiotic therapy with VSL#3, 1 packet (900 billion bacteria including *Lactobacillus*
30
31 species, *Bifidobacterium* supplementation, *Streptococcus salivarius* supplementation, and
32
33 *Thermophilus* supplementation) each day or placebo for 12 months after ileostomy closure. VSL#3
34
35 reduced the incidence of acute pouchitis—only 10% of patients that received VSL#3 (2/20) developed
36
37 pouchitis, while 40% of the placebo group (8/20) developed pouchitis ($P < 0.05$).⁸

38
39
40
41
42 The first-line treatment of acute pouchitis is empirical with antibiotics. Ciprofloxacin and
43
44 metronidazole are the most commonly used, often generating a rapid dramatic response after a 2- to 4-
45
46 week course (70% of remission), with rifaximin and tinidazole being alternative agents to try in
47
48 combination. Long-term use of antibiotics is poorly effective in achieving clinical remission for those
49
50 patients with chronic pouchitis, but may be useful at keeping symptoms under control.⁹

51
52
53
54 Patients with antibiotic-refractory pouchitis may need to opt for salicylates, corticosteroids (i.e.
55

1 budesonide), immunosuppressive drugs (i.e. azathioprine), or anti-TNF biologics.

2
3
4 Treatment of a recurrent episode of pouchitis should first be directed toward a repeat trial of antibiotics
5
6 or a trial of combination antibiotic therapy.
7

8
9 Patients who continue to have relapses of pouchitis despite antibiotics at least 3 times each year are
10
11 considered to have a chronic antibiotic-dependent pouchitis. These patients often require rotating
12
13 courses of antibiotics, and these patients should also be placed on maintenance therapy.
14

15
16 A randomized controlled trial of 40 patients given 2 packets/day of VSL#3 (600 billion bacteria) or
17
18 placebo showed that VSL#3 was able to prevent a relapse during the study follow-up period of 9
19
20 months (15% of VSL#3 had relapse vs 100% placebo, $P < 0.001$).⁸
21
22

23
24 Oral budesonide is used at 9 mg/day for 3 months, then 3–6 mg/day for maintenance. Steroid therapy
25
26 with budesonide has been tried in multiple small studies with reported remission rates of 60%–75%.
27

28
29 Another steroid, beclomethasone dipropionate, was tried in an open-label study of 10 patients for 8
30
31 weeks, and 80% of patients achieved remission based on a total PDAI < 4 .¹⁰
32
33

34 Topical mesalazine has been given to patients with pouchitis with clinical and endoscopic
35
36 improvement.
37

38
39 Immunosuppression with immunomodulators such as azathioprine or 6-mercaptopurine has also been
40
41 used by some providers, although little data exists regarding the use of immunomodulator monotherapy
42
43 for pouchitis.
44

45
46 Studies including small numbers of patients (often fewer than 20), and mostly retrospective in design
47
48 have demonstrated that infliximab appears to have good clinical effectiveness in selected patients with
49
50 pouchitis, achieving up to 80% short-term and around 50% long-term response. Some data suggest that
51
52 potentially, in some patients started on anti-TNF medications for pouchitis, we may be delaying
53
54
55

1 inevitable surgery rather than having a meaningful impact on disease course.¹¹

2
3
4 In an open-label, prospective, single arm, multicentre study was evaluated the efficacy of granulocyte
5
6 and monocyte apheresis in patients that had active pouchitis while on conventional medical therapy
7
8 including corticosteroids, amino-salicylates and anti-TNF biologics in addition to antibiotics. Nearly
9
10 half of the patients (46%) responded to the treatment, but without achieving complete remission.¹²

11
12
13
14 In a case series of 5 patients receiving multiple faecal microbiota transplantation (range 1–7) via
15
16 flexible sigmoidoscopy had symptom resolution in 80% (4/5) within 4 weeks, and 75% (3/4) of the
17
18 responders remained in remission for 3 months.¹³

19
20
21 Finally, case series about emerging role of vedolizumab or ustekinumab as a treatment option for
22
23 chronic have been published.^{14,15}

24
25
26 In conclusion, treatment of chronic refractory pouchitis remains an unmet need of UC' management.

27 28 29 30 31 32 **References**

- 33
34
35
36
37 1. Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during
38
39 the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN
40
41 Study). *Scand J Gastroenterol.* 2009 Jan 8;44(4):431–40.
- 42
43
44 2. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. *Br Med J.*
45
46 1978 Jul 8;2(6130):85–8.
- 47
48
49 3. de Buck van Overstraeten A, Wolthuis AM, Vermeire S, Van Assche G, Laenen A, Ferrante M,
50
51 et al. Long-term functional outcome after ileal pouch anal anastomosis in 191 patients with
52
53 ulcerative colitis. *J Crohn's Colitis.* 2014 Oct;8(10):1261–6.
- 54
55

- 1 4. Shen B, Fazio VW, Remzi FH, Delaney CP, Bennett AE, Achkar J-P, et al. Comprehensive
2 Evaluation of Inflammatory and Noninflammatory Sequelae of Ileal Pouch-Anal Anastomoses.
3
4 Am J Gastroenterol. 2005 Jan;100(1):93–101.
5
6
- 7 5. Lightner AL, Fletcher JG, Pemberton JH, Mathis KL, Raffals LE, Smyrk T. Crohn's Disease of
8 the Pouch: A True Diagnosis or an Oversubscribed Diagnosis of Exclusion? Dis Colon Rectum.
9
10 2017 Nov;60(11):1201–8.
11
12
- 13 6. GIONCHETTI P, RIZZELLO F, POGGIOLI G, PIERANGELI F, LAURETI S, MORSELLI C,
14 et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther.
15
16 2007 Feb 28;25(10):1231–6.
17
18
- 19 7. Shen B, Lashner BA. Diagnosis and treatment of pouchitis. Gastroenterol Hepatol (N Y). 2008
20
21 May;4(5):355–61.
22
23
- 24 8. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of
25
26 pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.
27
28 Gastroenterology. 2003 May;124(5):1202–9.
29
30
- 31 9. Segal JP, Poo SX, McLaughlin SD, Faiz OD, Clark SK, Hart AL. Long-term follow-up of the
32
33 use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. Frontline
34
35 Gastroenterol. 2018 Jan 31;9(2):flgastro-2017-100913.
36
37
- 38 10. Gionchetti P, Calabrese C, Calafiore A, Praticò C, Poggioli G, Laureti S, et al. Oral
39
40 beclomethasone dipropionate in chronic refractory pouchitis. J Crohn's Colitis. 2014
41
42 Jul;8(7):649–53.
43
44
- 45 11. Segal JP, Penez L, Mohsen Elkady S, Worley GHT, McLaughlin SD, Mullish BH, et al. Long
46
47 term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre
48
49 retrospective study. Scand J Gastroenterol. 2018 Sep 29;1–8.
50
51
- 52 12. Yamamoto T, Tanaka T, Yokoyama T, Shimoyama T, Ikeuchi H, Uchino M, et al. Efficacy of
53
54
55

1 granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for
2 ulcerative colitis: an open-label, prospective, multicentre study. *Therap Adv Gastroenterol*. 2017
3
4
5
6 Feb 25;10(2):199–206.
7

8 13. Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal Microbiota Transfer in
9 Patients With Chronic Antibiotic-Refractory Pouchitis. *Am J Gastroenterol*. 2016 Mar
10
11
12 28;111(3):441–3.
13

14
15 14. Philpott J, Ashburn J, Shen B. Efficacy of Vedolizumab in Patients with Antibiotic and Anti-
16
17
18 tumor Necrosis Alpha Refractory Pouchitis. *Inflamm Bowel Dis*. 2017 Jan;23(1):E5–6.
19

20 15. Peter J, Zeitz J, Stallmach A. Ustekinumab Rescue Therapy in a Patient With Chronic
21
22
23 Refractory Pouchitis. *J Crohn's Colitis*. 2018 Jul 30;12(8):1008–9.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55